Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: January 2007
-
By Christopher P. Singer — In a January 24, 2007 press release, Roche announced that its multinational phase III study of Actemra (tocilizumab) for treatment of rheumatoid arthritis has met its endpoint. The study focused on patients with rheumatoid arthritis that had poor response to treatment with methotrexate. Over the course of the…
-
By Christopher P. Singer — In a rule change that is sure please patent practitioners living in Hawaii, the U.S. Patent and Trademark Office (USPTO) announced several amendments to Title 37 of the Code of Federal Regulations (C.F.R.) relating to EFS-Web correspondence. In particular, the following sections of 37 C.F.R. have been…
-
By Donald Zuhn — On January 22, 2007, the Federal Circuit announced a proposal to amend its rules by adopting Federal Circuit Rules 28(a)(15) and (16), 28(j), 30(k), and 31(b), (e), and (f); and by deleting Federal Circuit Rule 32(e). According to the Court's announcement, the rule changes would require parties represented by…
-
By Donald Zuhn — In an appeal from a District Court decision granting summary judgment in favor of Defendant-Appellee Caraco Pharmaceutical Laboratories, Ltd. (Caraco), the Federal Circuit concluded that the District Court did not err in construing the term "about 1:5" or in finding no literal infringement or infringement under the doctrine of equivalents,…
-
By Jason Derry — As discussed by Gareth Dixon and Jacinta Flattery-O'Brien of Shelston IP, a bill has been passed by Australia's Federal Parliament that allows otherwise infringing activities to be carried out for the purposes of obtaining regulatory approval. The bill allows generic companies to obtain approval for products during the patent term…
-
January 29-30, 2007 – Biotechnology 2007 (Law Seminars International) – San Francisco, CA January 29-30, 2007 – BIO-Asia Partnering Conference (Biotechnology Industry Organization) – Tokyo, Japan February 27-28, 2007 – Patent Portfolio Management (American Conference Institute) – New York, NY April 16-18, 2007 – Biotechnology: Patent Prosecution, Licensing, Litigation & Hatch-Waxman (Patent Resources Group) –…
-
By Donald Zuhn — Further to yesterday's report, the United States Patent and Trademark Office (USPTO) announced today that applicants can now request electronic transfer and retrieval of priority documents to and from the European Patent Office (EPO). The USPTO also announced that later this year, applicants will be able to request…
-
By Donald Zuhn — As reported here earlier, the U.S. Patent and Trademark Office (USPTO) has now promulgated a final rule providing for the electronic transfer of certified copies of priority documents from other intellectual property offices and permitting other intellectual property offices to electronically retrieve certified copies of U.S. patent applications…
-
By Mark Chael — Meridian Biosciences, Inc. (Nasdaq: VIVO) of Cincinnati, OH recently announced that its subsidiary, Meridian Life Sciences, Inc., has manufactured an infectious inoculum of respiratory syncytial virus (RSV) to be used in human challenge studies of healthy volunteers. RSV is an enveloped RNA virus and the most common cause…
-
By Jason Derry — In May 2006, XOMA Ltd. and Schering-Plough Corp. agreed to a collaboration relating to discovery and development of therapeutic monoclonal antibodies. Under the agreement, Schering-Plough selects the targets and XOMA uses its proprietary antibody technology to discover antibodies of therapeutic interest. On Wednesday, XOMA announced that Schering-Plough exercised…
Patent Docs 